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Ligand-Selective Inhibition of the Interaction
of Steroid Receptor Coactivators
and Estrogen Receptor Isoforms
SRC2, and SRC3, has been proposed by O’Malley and
is adopted in this report. Homozygous disruption of the
genes encoding each SRC causes fairly distinct pheno-
types in mice, thus suggesting the possibility of distinct
mechanisms or activities for each SRC [17, 18]. How-
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of SRC2 following disruption of SRC1, indicating the600 16th Street
San Francisco, California 94143 possibility of partially overlapping function. The underly-
ing biochemical mechanisms that may allow for conser-
vation or separation of SRC function in ligand-depen-
dent signaling are poorly understood. Inhibitors thatSummary
would allow selective disruption of particular NR•SRC
interactions in vivo would be very useful in elucidatingLigand-dependent nuclear hormone receptor (NR) sig-
such mechanisms.naling requires direct interaction between NR and the
Genetic and biochemical studies have identified thesteroid receptor coactivators (SRC). Herein we utilize
NID of the SRCs, which contains multiple interactiona library of SRC2 peptidomimetics to select for specific
motifs known as NR boxes, each with a consensus se-inhibitors of the interaction of SRC2 with the two estro-
quence of L1XXL2L3 [3, 5]. The NR•SRC protein-proteingen receptor (ER) isoforms, ER and ER, in the pres-
interaction is highly conserved across the NR superfam-ence of three different ligands: 17-estradiol, diethyl-
ily, with these coactivators seemingly shared by moststilbesterol, and genistein. The pattern of inhibitor
or all of the NR proteins. An analogous motif (I/LxxII)selectivity for each ER isoform varied depending upon
has been identified for corepressors SMRT and NCOR,which ligand was present, thus demonstrating that the
and the binding sites for coactivator and corepressorligands exert unique allosteric effects upon the surface
may be partially overlapping [19, 20]. It appears thatof the SRC binding pocket. Several of the lead com-
corepressors can also utilize an analogous motif to me-pounds are highly (100-fold) selective for blocking
diate their interaction with NR in some contexts [21, 22].the binding of SRC2 to ER, in preference to ER, in
Each NR box of the SRCs NID can have differentthe presence of one ligand and therefore may prove
affinities for a particular NR•ligand•promotor triad anduseful for decoupling ER signaling from ER sig-
can bind in a cooperative [23] or noncooperative [24,naling.
25] manner. Despite recent findings of additional inter-
actions of SRC with NR outside the NID [26], blocking
Introduction the interaction of NR and SRC in cellular models by
overexpression of fusions of SRC NR box peptides in-
The nuclear receptor (NR) superfamily of hormone- hibits gene transcription from elements normally re-
induced transcription factors integrates specific signals sponsive to hormone-induced signaling [27]. Short NR
to properly regulate distinct physiological responses in- box peptides and -helical peptidomimetics containing
cluding development and dynamic homeostasis [1, 2]. the NR box sequence can effectively compete with the
Misregulation of these signals has been directly corre- entire NID of the SRC2 [24]. For example, hER, hER,
lated with disease states, including various forms of and hTR share the use of SRC2 despite the fact that
cancer and metabolic diseases [3]. The NR can act as they regulate entirely different gene transcription path-
simple transcription factors (where they are the only ways [28]. In vitro, hTR and both ER isoforms tightly
DNA binding factor in the complex), as complex factors bind the second NR box of SRC2 (SRC2-2), 685EKHKIL1(where they work in concert with other DNA binding ERL2L3KDS697, in the presence of their native ligandsfactors), or as tethered factors (where their interaction thyroid hormone (T3) and estradiol (E2), respectively. Thewith DNA is mediated by another protein) [4]. In ligand- ER isoforms also interact with SRC2-1 with lesser affinity
dependent signaling, they generally function to activate while the TRs interact with SRC2-3.
transcription at simple elements by the recruitment of The estrogen receptors have distinct biological re-
a family of cofactors, the steroid receptor coactivators sponses to different natural and synthetic estrogen-like
(SRCs), through the binding of the SRCs’ nuclear recep- ligands [29–31], so-called selective estrogen response
tor interaction domain (NID) [3, 5] (Figure 1). The SRCs modulators (SERMs). The effect of the ligand depends
themselves have several well-characterized activation primarily on the ability to alter the structure, stability,
domains: one that recruits CBP/p300 [6], another that and interactions of the receptor LBD [32]. Estrogen and
recruits CARM, an arginine methyltransferase [7], and a estrogen-like ligands function by binding with high affin-
domain with histone acetyl transferase activity. There ity to the ligand binding domain (LBD) and partially filling
are at least three SRCs: SRC1, SRC2/GRIP1/TIF2, and the hydrophobic core of the domain. The ligands alloste-
SRC3/ACTR/Rac3/pCIP/AIB1 [8–16]. A unified nomen- rically define the overall LBD structure by creating a
clature, in which the proteins are referred to as SRC1, conformational change in the LBD that promotes or in-
hibits the binding of coregulator proteins. The ER iso-
forms bind SRC2-2 when liganded with either the syn-*Correspondence: rguy@cgl.ucsf.edu
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Figure 1. Ligand-Dependent Nuclear Receptor Regulatory Transcription Complex Assembly
Schematic model of the dynamic assembly of the transcription activation complex by agonist-bound estrogen receptor (ER) and function of
steroid receptor coactivator (SRC) binding inhibitors. From left to right: In the absence of ligand, chromatin is unmodified and transcription
at the DNA estrogen response element (ERE) is unaltered. Binding of agonist ligand to the ligand binding domain (LBD) of ER induces a
conformational change in ER, leading to translocation and homodimerization on the ERE. Liganded ER on the ERE recruits SRCs using the
NR box (L1XXL2L3) of the nuclear receptor-interacting domain (NID). Subsequently, the ER•SRC complex recruits other coregulator proteins
and transcription factors to form the activation complex where chromatin is modified and transcription of the ERE gene commences. Direct
competitive inhibition of SRC binding to NR will block the initial step of activation complex formation and thus prevent transcription.
thetic partial agonist diethylstilbesterol (DES) or with the These unique characteristics of each receptor interface
allow nonnatural LXXLL peptidomimetics to selectivelyphytoestrogen genistein (Gen) [33]. Depending on the
physiological context, the receptor isoform, and pres- inhibit the interaction. For example, when targeting three
homologous nuclear receptors (hTR, hER, and hER)ence of particular coactivators, this combination may
result in an estrogenic, partial estrogenic, or an anties- liganded with their physiological ligands, we found ten
peptidomimetics that were selective for hER, one thattrogenic response [34]. Until now, the focus of studies
of ligand allosteric effects has been on gross structural was selective for hER, and one that was selective for
hTR by at least 10-fold [42].changes of the LBD, such as the repositioning of helix
12 and its ability to create or conceal the SRC binding Herein we report our analysis of the structural founda-
tion of this observed selectivity and the examination ofpocket.
Structurally, the interactions of hER and hTR with the ligand-dependent allosteric modulation of the ER:
SRC2-2 interface by three related ligands: estrogen, di-the SRC2-2 peptide are very similar to those of other
NR•coactivator structures solved to date [22, 24, 32, ethylstilbesterol, and genistein. In vitro competition
studies show that these binding sites are allosterically35–37]. Each seems to interact through similar surfaces
with a shallow hydrophobic groove on the NR surface modulated by the different ligands in a way that permits
the differential selection of SRC2-2 peptidomimetic in-binding to an induced fit, amphipathic, -helical motif
on the SRC2-2 NR box, burying the conserved three hibitors without significantly altering the binding of the
native SRC2-2 NR box.leucines on the hydrophobic face of the NR box helix.
While each of the leucines in the NR box is critical to
the interaction [38], in vivo specificity in recruiting a Results and Discussion
particular SRC appears to be induced by the sequences
immediately flanking the NR boxes [27, 33, 37, 39] rather Structural Analysis of NR•SRC Interactions
At the protein fold level, the differences between the NRthan the geometry of the leucine side chains. Manipula-
tion of NR box peptide sequence outside of the con- coactivator interfaces (Figures 2B–2D) of T3•hTR•
SRC2-2 [24], DES•hER•SRC2-2 [32], and E2•hER•served L1XXL2L3 motif has afforded selective peptide
inhibitors of the interaction of particular NR and SRCs, SRC2-3 [44] appear minimal. Each of the SRC2 peptide
main chain rmsd’s is less than 1.0 A˚, and the receptorpresumably by taking advantage of these extended in-
teractions [27, 40, 41]. However, such extended ele- main chain rmsd’s are less than 2.0 A˚. However, upon
closer investigation, we find that there are differencesments would not be available to a small molecule dis-
rupting the interaction, and it is therefore uncertain how in the side chain positions within each pocket and within
pocket surfaces that alter the electrostatics, topogra-such findings reflect upon the development of such a
drug. phy, and the location of solvent-accessible volume be-
tween the pockets of each receptor (Figures 2E and 2F).As our approach targets such drugs, it was paramount
to identify subsite-specific differences within the small In particular, comparing hTR and hER reveals that
hER (Figure 2C) has a ridge with a continuous electro-hydrophobic pocket that binds the NR box that could
be effectively utilized by a small molecule. We therefore static potential adjacent to the L2 subpocket, whereas
hTR (Figure 2B) has a subpocket that is sterically hin-rationally designed a series of SRC2-2 NR box mimetics
[42] with one of three leucines substituted on a con- dered by a more significant plateau with a gradient of
electrostatic potential. Additionally, a pronounced ridgestrained peptidomimetic scaffold [43]. Despite the high
degree of structural conservation in these interfaces, it in hTR creates more steric hindrance between the L1
and L3 subpockets than what is present in hER. A totalis apparent from our recent studies that there are subtle
differences in the hydrophobic interface of each NR. of 19 amino acid side chains on the surface of both
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Figure 2. Phylogenetic and Structural Comparison of Three Cocrystal Structures Highlighting Significant Differences in the Subsites of Each
Nuclear Receptor Interface
(A) Alignment of the primary amino acid sequences that make up the coactivator binding pockets of the receptors hTR, hER, and hER.
The secondary structure of the proteins is identified in gray with each helix numbered according to the convention for NR. Amino acids are
shown in single-letter format with residue numbers from the receptor primers beginning and ending each segment. The NR signature sequence
is shown on top with (φ) indicating an aromatic residue, (A) indicating alanine, (b) indicating a basic residue, (h) indicating any hydrophobic
residue, (P) indicating proline, (L) indicating leucine, (Q) indicating glutamine, and (q) indicating a charged residue. Blue denotes areas of the
receptor that make contact with the respective native ligands of each receptor. Red denotes residues identified to form VDW interactions
with the leucine side chains of SRC2-2 in the respective crystal structures. Green denotes residues that compose the hydrophobic pocket
and are buried in the crystal structures. An asterisk indicates residues that are buried in the respective complexes and are different between
the hTR and the two ER isoforms but are the same between the isoforms; () indicates the residues that are the same across all the receptors;
and () indicates residues that different across each receptor. This clearly demonstrates differences in the side chain character of the SRC
binding pocket. () indicates residues that have a different type of interaction with the coactivator.
(B–G) Cocrystal structure of the SRC NR box binding pocket in: (B) T3•hTR•SRC2-21, (C) DES•hER•SRC2-22, and (D) E2•hER•SRC2-3. The
SRC binding pocket in each cocrystal structure is shown as a cross-section through the L1 and L3 recognition pockets to highlight structural
and electrostatic differences within the highly conserved binding pockets. The three leucine side chains of the SRC2-2 (L1XXL2L3) and the
SRC2-3 (LLTXXLL) motifs (yellow wire frame) are labeled L1 L2 L3. Each receptor Conolly surface was generated with a probe of 1.4 A˚ radius
and color coded to induce a continuous electrostatic gradient (Sybyl). These views demonstrate clear significant differences in steric structure
and electrostatics between the hTR and hER SRC binding pockets (B versus C) as well as potential plasticity within hER surface (C versus
D). These structural and volumetric differences between each comparison are highlighted in (E) and (F) with difference maps consisting of
2.2 A˚ radius spheres that differentially fill each pocket of each receptor. (E)–(G) are oriented the same as (B)–(D): (PyMOL) spheres of 2.2 A˚
radius filled the solvent accessible volume of each receptor pocket. Spheres were compared and removed if shared between receptor pockets,
leaving only those that were present in one structure and not the other. In (E), blue web spheres highlight the location of eight spheres totaling
357 A˚3 of volume that is available in the hER pocket and not in the hTR pocket. In F, six red spheres locating 268 A˚3 of volume that is
available in hTR and not hER. (G) shows a similar comparison between the pockets of (C) DES•hER•SRC2-2 and (D) E2•hER•SRC2-3,
with blue denoting the location of nine spheres totaling 401 A˚3 present in the pocket of DES•hER•SRC2-2 and not in E2•hER•SRC2-3; and
the reverse comparison also showing nine red spheres but in different locations. This highlights that the pocket has changed in topography
without a change in accessible volume, possibly due to the change in ligand or in response to the different SRC-interaction motif.
hER and hTR are either buried by SRC2-2 or form ing, see Figure 2). Eight of these form unique direct
contacts (underlined) with the leucines of SRC2-2 in onedirect contacts with the NR box (Figure 2A). Only eight
of these amino acid residues are conserved between receptor and not the other, while two residues (C381G
and A382C) are buried in the TR pocket but not withthe two receptors. Fifteen of the 19 residues are different
between TR and ER by sequence or degree of physi- ER. Four nonconserved residues (L354I, M357V, I358V,
and V364L) are conservative substitutions, while sixcal interaction with the SRC2-2 NR box leucines (L354I,
V355T, M357V, I358V, V364L, V368C, L372C, V376I, (V355T, V368C, L372C, C381G, A382C, and D538P) ex-
hibit large changes in shape, electrostatics, or hydrogenE380K, D538P, M543V F367F, and Q375Q; ER number-
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bonding potential. The presence of four surface- trogen analog diethylstilbesterol (DES) and the phytoes-
trogen genistein (Gen), both partial agonists that haveexposed cysteines in the coactivator binding pocket on
TR is somewhat surprising and may point to a potential been shown to recruit SRC2-2 to both ER isoforms.
This peptidomimetic library utilizes an -helical scaf-for regulation of coactivator binding by oxidative post-
translational modifications such as nitrosylation, which fold (Figure 3A) [43]: a conformationally constrained NR
box peptide 1{37,37,37} that functionally disrupts thehave been observed with other transcription factors [45].
The relative location and substitutions of proline and interaction of SRC2 and hTR. Peptidomimetic 1{37,
37,37} binds to hTR 15-fold better than the nativeglycine between ER and TR are of some interest and
may reflect potential for greater flexibility of secondary SRC2-2 peptide: 10.8M and 0.79M, respectively [43].
We utilized this lead compound as a constrained helicalstructure in ER.
The two ER isoforms have 59% homology in the ligand scaffold for the presentation of a library of compounds
with nonnatural amino acid side chains that mimic eachbinding domain [46], suggesting that achieving selectiv-
ity between them would be difficult. Assuming that ER of the three leucines within the LXXLL motif. Each mem-
ber of this library was comprised of a unique compound,and ER interact with the SRC2-2 peptide similarly (no
cocrystal structure of ER•SRC2-2 is available), only 2 synthesized in parallel, that had one of the leucines
changed to a nonnatural amino acid—predominantlyof the 19 residues lining the pocket are different between
the ER isoforms. V364I is a fairly conservative change, substituted phenylalanines and phenylglycines. Each li-
brary member was purified by RP-HPLC, and purity andwhile D538Y (hER numbering) is a major change. Two
spatially adjacent substitutions (C381S and A382C) identity were confirmed prior to use [42].
The competitive ability of each of the library memberspresent changes in electrostatic or hydrogen bonding
potential. to inhibit the binding of SRC2-2 to the two ER isoforms
was assessed using a fluorescence polarization equilib-To aid analysis, we generated volume maps of the NR
box binding sites for the receptors and quantitatively rium competition assay as previously described [42].
The OG-SRC2-2 probe bound to each receptor in a li-subtracted them from one another to compare differ-
ences (Figures 2E–2G). This analysis revealed that there gand-dependent manner with Kds of 299 nM, 310 nM,
and 450 nM for E2•hER, DES•hER, and Gen•hER,is 357 A˚3 available in the ER pocket that was not ad-
dressable from the hTR pocket (Figure 2E) and 268 A˚3 and 370 nM, 450 nM, and 520 nM, for E2•hER, DES•
hER, and Gen•hER, respectively. The lead compoundavailable in hTR but not in hER (Figure 2F). A similar
comparison of hER with two different ligands and dif- 1{37,37,37} competed for each of these interactions with
SRC2-2 with IC50 values of 120 nM, 290 nM, and 110 nMferent SRC2 peptides, DES•hER•SRC2-2 and E2•hER-
•SRC2-3 [44], shows significant differences within the for E2•hER, DES•hER, and Gen•hER, and 151 nM,
261 nM, and 350 nM for E2•hER, DES•hER, andpocket (Figure 2G). There is not a change in the overall
volume of the pocket but rather a change in the location Gen•hER, respectively. There is little selectivity be-
tween isoforms with the lead compound relative to theof solvent accessible volume. However, this last com-
parison is complicated by the multiple differences in the natural affinities of SRC2-2. The entire library was then
screened with each receptor•ligand pair. Surprisingly,crystallization conditions of hER (including ligand and
peptide partner), which prevent unambiguous assign- many of the compounds that were previously identified
to inhibit the E2•hER interaction with SRC2-2 did notment of surface differences to the change in the ligand,
the change in NR box peptide sequence, or both. inhibit interaction with either one or both of the DES- or
Gen-bound hER. Likewise, several of the compoundsOverall, this analysis confirmed that, while the differ-
ences in the coactivator binding pockets are subtle, that did not seem to target E2•hER inhibited the SRC2-2
interaction with DES•hER or Gen•hER (Figure 3B).there is typically at least 250 A˚3 in volume change and
accompanying changes in electrostatics from NR• The selectivity of twelve inhibitors changed by 10-fold
for hER in a ligand-dependent fashion. At L1, the para-ligand pair to pair. In general, the large number of signifi-
cant changes in residues involved in coactivator binding fluorophenylglycine 1{3,37,37} effectively targeted only
the DES•hER form of the receptor. At L2, the meta-partially explains our ability to find specific inhibitors
targeted at this pocket [42]. However, as will be dis- trifluoromethylphenylglycine 1{37,9,37} targeted E2•
hER, the cyclohexylalanine 1{37,20,37} was selectivecussed below, they do not allow for computational pre-
determination of selectivity. for both the E2 and DES liganded forms of hER, the
cyclopentylphenylglycine 1{37,28,37} was selective for
DES over Gen but not between DES and E2, and trypto-
Screening for Ligand•NR-Selective phan 1{37,34,37} is highly selective for the DES-bound
Peptidomimetics form of hER. At the L3 position, three phenylglycine
Previous reports of the effects on ER and ER interac- compounds were selective for E2: 2,3-Difluorophenyl-
tions with SRC2-2 peptides in the presence of these glycine, 3,4-Difluorophenylglycine, and 1,5-Difluorophe-
ligands indicated that there was little change in the re- nylglycine, 1{37,37,4}, 1{37,37,5}, and 1{37,37,6}. The or-
cruitment of the individual boxes [33]. While the ligands tho-chlorophenylalanine 1{37,37,14} and tryptophan
do not significantly perturb the binding of the native 1{37,37,34} selected for the DES•ER ligand (Figure 3C).
LXXLL NR box motifs, our analysis indicated that the The specificity of sixteen inhibitors changed for hER
hydrophobic pocket was being modulated in such a way between the three ligands. At the first leucine position
that the binding of other nonnatural leucine mimetics L1, the phenylglycine 1{1,37,37} was selective for DES
would be significantly effected. To explore this idea, and Gen over E2. The cyclohexylalanine 1{20,37,37} and
we screened the library against hER and hER in the cyclopentylphenylalanine 1{29,37,37} were selective for
both E2 and DES over Gen. At position L2, phenyl glycinepresence of different ligands, including a synthetic es-
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Figure 3. The Scaffold Design and Estrogen Receptor Isoform Ligand-Dependent Inhibitory Selectivity Profile of the SRC2-2 Proteomimetics
(A) The structure of the proteomimetic library scaffold 1{X,X,X} with diversity positions indicated by L1, L2, and L3. 1{37,37,37}: L1  L2 
L3  LEU.
(B) The relative equilibrium 50% inhibitory concentration (IC50) for each library member for competition of the SRC2-2 peptide from each ER
isoform (hER or hER) in the presence of three ligands (E2, DES, Gen) as determined by two separate quadruplicate in vitro fluorescence
polarization evaluations is presented in a colorimetric scale that has been normalized to the IC50 values of the lead compounds 1{37,37,37},
with gold indicating an IC50 100 M, dark blue indicating an IC50 of	100 nM, and gradations of color between the two indicating intermediate
IC50 values. White boxes denote compounds whose synthesis was not achieved. Individual nonnatural amino acids are arrayed on the y axis
and numbered according to each nonnatural side chain, as previously described. The x axis depicts the position of nonnatural amino acid
substitution (L1, L2, or L3) and the NR tested. Actual values and the 95% confidence range are presented in Supplemental Tables S1–S3.
(C) Selective inhibitors with 50-fold selectivity. The selectivity profile of SRC2-2 proteomimetic inhibitors that are specific to one NR/ligand
by 50-fold due to individual side chain substitutions at one Leu position. Selectivity among the tested NR is indicated on the right side with
the fold decrease in the IC50 relative to the IC50 against the receptor for which the compound is most selective. Structures of six library
members that change their selectivity for hER and hER in a ligand-dependent fashion (hER and hER were tested in the presence of
estrogen (E2), the SERM diethylstilbesterol (DES), and the phytoestrogen genistien (Gen).
(D) The structures of 14 inhibitors that were selective for hER over hER with each ligand.
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1{37,1,37} was selective for DES and Gen over E2, while inhibitors would not fit into the pocket unless the van
der Waals constraints were relaxed by 0.2 A˚ (data not1{37,4,37} and 1{37,5,37} were selective for both E2 and
Gen over DES and 1{37,14,37} was selective for E2. At shown). These compounds represent selectivity that
could not be predicted computationally.position L3, five phenyl glycines were selective for both
DES and Gen over E2: 1{37,37,1}, 1{37,37,2}, 1{37,37,3}, ER clearly tolerates larger groups within the NR box
binding pocket than the crystal structures indicate1{37,37,5}, and 1{37,37,8}; of the phenylglycines, 1{37,
37,12} was selective for E2 and Gen, while 1{37,37,14} would be possible. This finding is most likely explained
by one of two models: (1) the SRC peptidomimetic inhibi-was selective for E2; 1{37,37,20} was selective for E2 and
Gen over DES; 1{37,37,24} was selective for DES; and tors are binding in a different orientation than what is
seen from the native peptide crystal structures, and/or1{37,37,29} was selective for DES and Gen over E2. Six
compounds changed their affinity for hER or hER in (2) the surface of hER is plastic and is responding to
the inhibitors in a way that permits these compoundsa ligand-selective manner by 50 fold (Figure 3C).
A total of 19 inhibitors were selective for hER over to unveil new subsites that are energetically favorable.
The latter may be possible due to the reduced entropichER by 10-fold or more when the receptors were li-
ganded with E2: four with substitutions at L1 (1{6,37,37}, cost of peptide helix formation translating into additional
binding energy that perturbs the receptor surface differ-1{10,37,37}, 1{32,37,37}, 1{34,37,37}), four at L2 (1{37,
1,37}, 1{37,9,37}, 1{37,16,37}, 1{37,20,37}), and 11 at L3 ently than the crystal refined state.
(1{37,37,1}, 1{37,37,3}, 1{37,37,8}, 1{37,37,13}, 1{37,37,
19}, 1{37,37,22}, 1{37,37,24}, 1{37,37,26}, 1{37,37,29},
Discussion1{37,37,32}, 1{37,37,34}). Fifteen inhibitors were selec-
The SRC binding pockets of NR have evolved to bindtive for hER over hER when bound to DES: three with
to a simple hydrophobic L1XXL2L3 consensus motif whilesubstitutions at L1 (1{16,37,37}, 1{32,37,37}, 1{34,37,37}),
relying upon differences in SRC sequences flanking theseven at L2 (1{37,4,37}, 1{37,7,37}, 1{37,9,37}, 1{37,
NR box to convey selectivity in vivo. Our studies show19,37}, 1{37,20,37}, 1{37,34,37}, 1{37,35,37}), and five
that ER has a tolerance and even strong selection forat L3 (1{37,37,12}, 1{37,37,23}, 1{37,37,27}, 1{37,37,32},
aromatic moieties replacing the leucine side chains1{37,37,34}). Six were selective for hER in the presence
when presented on an appropriate peptidomimetic scaf-of Gen: three with substitutions at L1 (1{1,37,37}, 1{20,
fold. This observation is in stark contrast to prior studies37,37}, 1{34,37,37}), one at L2 (1{37,11,37}), and two at
with expressed peptide libraries [27, 41] that did notL3 (1{37,37,22), 1{37,37,36}). Two of the inhibitors were
select for phenylalanine, possibly due to its negativeselective for hER: the previously identified ortho-chlo-
effect on the helicity of unconstrained peptides. Ourrophenylalanine at L2, 1{37,14,37}, in the presence of E2,
studies reveal that the NR box binding pockets of theand tryptophan at L3, 1{37,37,34}, in the presence of
NR contain significant differences in shape and electro-Gen. Fourteen of these inhibitors were specific to hER
statics that allow competitive inhibitors that mimic thewith 50-fold selectivity over hER in the presence of
NR box to act selectively between NR and even betweenone of the three ligands (Figure 3D). This set represent
the same NR when a different is ligand bound.the most promising leads for physiologic study or novel
These results were only obtained by utilizing a con-therapy. Each of these compounds has the potential to
strained scaffold that removes the entropic cost of helixhighly selectively abrogate ER signaling induced by a
formation in this induced-fit  helix protein-protein inter-particular ligand without affecting that of ER.
action. Other methodologies utilizing linear peptide li-
braries composed of natural amino acids have been
unable to select for side chains other than leucine withAnalysis of Structural Determinants of Selectivity
The interaction modes of a number of the selective inhib- these receptors [27, 41]. Linear peptides with a phenylal-
anine substituted at each of the leucine positions ofitors were evaluated using DOCK (Figures 4A–4F). Com-
paring the results of the in silico CombiDOCK screening a similar peptide from the SRC2-2 (KHKIFHRLLQDSS,
KHKILHRFLQDSS, and KHKILHRLFQDSS) [24] reducedand the in vitro competition data of the same library
reveals that while this method was very useful for en- the competitive ability of the SRC2-2 peptide by 60- to
100-fold, the worst being the L1 substitution [24]. Here,hancing the likelihood of the library producing compe-
tent inhibitors, it was not effective for predicting selectiv- we clearly show that such phenylalanine replacements,
as well as substituted phenylalanine analogs, are ableity between the NR. Many of the compounds scored
similarly between the receptors and in almost identical to inhibit SRC2-2 binding quite well. Tryptophan, which
has not been selected in genetic screens, also clearlyminimized positions. The only correlation related to se-
lectivity that is apparent between the in silico and in works well in a constrained peptide background. It is
our belief that these larger side chains fit quite well intovitro binding studies is the size of the side chains. Larger
residues at positions L1 and L3 score slightly better when the interface, but only when presented on a properly
folded  helix. This apparent disparity suggests that theDOCKed with DES:hER than T3:hTR, and that trend
is apparent in the competition assays. Several DOCKed previous hypothesis that these NR cannot tolerate the
larger side chains may be incorrect. An alternate expla-inhibitor structures seemed to take advantage of the
differences that were identified by the structural and nation consistent with both sets of data is that the effect
of each residue on the helicity of the given peptide se-volumetric analysis (Figures 2B–2G). Peptidomimetics
1{37,8,37} and 1{37,37,14}, for example, bury solvent quence, in combination with the size-shape comple-
mentarity to the receptor surface, controls affinity. Thisaccessible volume that was identified in ER and not
in TR (Figure 4). However, a number of the selective hypothesis begs the question: are their other, yet to be
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Figure 4. DOCKed Structures of Two Selective Inhibitors
(A–C) The energy minimized structure of the hER•DES-selective inhibitor 1{37,8,37} with o- trifluoromethylphenylglycine replacing the second
leucine of the NR box. 1{37,8,37} scored the highest in the docking studies with both receptors hER•DES and hTR•T3.
(D–F) The inhibitor 1{37,37,14} with o-chlorophenylalanine replacing the third leucine of the NR box, which scored better with hER•DES than
with hTR•T3. Each of the DOCKed inhibitor structures was similar in orientation to that of the crystallographic coordinates of SRC2-2. The
rmsd values were as follows: 1{37,8,37} at 	0.2 A˚ and 1{37,37,14} at 	0.6 A˚. A number of selective inhibitors would not DOCK in the normal
orientation without relaxation of the restrictions to maintain the normal relationship between the peptide backbone and the receptor.
identified, NR interactions at this site with proteins that this may be a common situation in signaling interactions
that function dynamically with relatively weak affinity forhave different sequences? These could easily include
larger side chains that are stabilized into -helical sec- their partners. These systems may represent a particu-
larly tractable subset of protein interactions for inhibitorondary structures by their tertiary structures. A second
interesting question arises: how do the flanking se- development. The successful identification of specific
inhibitors of the E2•hER•SRC2-2 protein interaction uti-quences around the NR box LXXLL motif drive selectiv-
ity? Is it due to their direct contacts with the receptor lizing nonnatural -amino acids in an -helical pepti-
domimetic library demonstrates the feasibility of specifi-surface, as has been previously suggested [27, 41], or
is it due to some effect on helicity? The notion that they cally targeting the competition of protein interactions
where consensus motifs consist entirely of a small hy-make particular contacts with the receptor surface to
drive the interactions has been difficult to verify both drophobic patch. This preliminary study has already
yielded inhibitors of ER interactions with SRC2 thatstructurally and biochemically. The flanking sequences
could engender different levels of helicity by effecting are functionally selective for that isoform in preference
to effecting interactions of ER.helix dipole or through specific contacts. Additionally,
there may be transient interactions with the surface of
the receptors that seed the induction of helicity, as has Significance
been recently suggested [44].
Another finding arising from our data is that the partial Ligand-dependent nuclear hormone receptor (NR) sig-
naling requires direct interaction between NR and theER agonists are allosterically modulating “subsites” of
the leucine recognition pockets without perturbing the steroid receptor coactivators (SRC), effected by a se-
ries of conserved SRC motifs that are composed ofinteractions of the native LXXLL NR box sequences.
This suggests that one could potentially simultaneously three leucines (NR box, L1XXL2L3). We have previously
shown that peptidomimetics of the second NR boxtarget one receptor with, for example, an ER isoform-
specific ligand and a SRC peptidomimetic inhibitor that of SRC2 (SRC2-2) can exploit structural differences
between the NR box binding pockets of the thyroidis selective for that combination.
A similar failure to evolve tight shape complementarity hormone receptor  (TR) bound to thyroid hormone
(T3), and the two estrogen receptor (ER) isoforms (ERbetween receptor and peptide ligand has been observed
in the interactions of SH3 domains [47]. It seems like and ER), each bound to estrogen (E2). In this report,
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Supplemental Datawe demonstrate that the same library of SRC2-2 pepti-
Supplemental data including full experimental details of library com-domimetic inhibitors can take advantage of differ-
position and quality control, biochemical procedures, and tables ofences between the NR box binding pockets of ER
IC50 data and CD data is available at http://www.chembiol.com/cgi/and ER in the presence of three different ligands, content/full/11/2/273/DC1.
17-estradiol (E2), diethylstilbesterol (DES), and gen-
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